Researchers at Calluna Pharma AS, Agiana Pharmaceuticals AS and Roskilde University have developed the first humanized IgG4 antibody that inhibits S100A4, which is a calcium-binding protein that helps drive fibrotic inflammatory diseases.
In a new publication in Molecular Therapy, researchers from Paracelsus Medical University, Salzburg, Austria, and collaborators present a promising prime editing strategy for junctional epidermolysis bullosa (JEB) treatment.
Brainxell Inc. has reported preclinical data demonstrating efficacy of BXT-110, an autologous induced pluripotent stem cell (iPSC)-derived neuronal therapy for Parkinson’s disease.
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Frontier Medicines Corp. presented a first-in-class covalent activator of p53 Y220C with high potency and selectivity in restoring p53 tumor suppressor function.
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter.
Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for two of Kaigene’s nonclinical-stage assets, KG-006 and KG-002. Kaigene’s pipeline leverages its technology to selectively degrade pathogenic antibodies that mainly exacerbate various autoimmune diseases.
In atopic dermatitis (AD), the itch-scratch cycle is tied to skin inflammation exacerbation that accelerates the progression of the disease, thus impacting the patient’s quality of life, where IL-31 is crucial to induce skin itching. Helixon Ltd. has developed a bispecific antibody targeting both IL-31 and OX40L, HXN-1022, for the treatment of AD.
Oncolytic viruses are a potential therapeutic approach that uses viruses to selectively infect and kill cancer cells. In a new publication in Cell Reports Medicine, researchers from Heinrich-Heine-Universität Düsseldorf and Abalos Therapeutics GmbH show that tumor-tropic mutations in lymphocytic choriomeningitis virus (LCMV) enhance selective replication in cancer cells.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
